MedTrace Logo

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

NCT04268888 · Status: SUSPENDED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 522

Last updated 2025-02-26

No results posted yet for this study

Summary

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

Conditions

Interventions

DRUG

Nivolumab and TACE/TAE

Immunotherapy and TACE/TAE

PROCEDURE

TACE/TAE

TACE/TAE (as per local practice)

Sponsors & Collaborators

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Daniel Palmer, PhD, MD · Clatterbridge Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-08
Primary Completion
2025-08-01
Completion
2026-06-30
FDA Drug
Yes

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268888 on ClinicalTrials.gov